CARBON FOOTPRINT OF INDUSTRY-SPONSORED LATE-STAGE CLINICAL TRIALS

Carbon footprint of industry-sponsored late-stage clinical trials

Objectives To quantify the carbon footprint from a sample of pharma industry sponsored phase III trials.To develop an approach that can readily be applied to future trials by AstraZeneca and other trial sponsors.Design Life cycle assessment including all the sources of carbon emissions associated with a completed, an ongoing and a planned clinical

read more

Asn563Ser polymorphism of CD31/PECAM-1 is associated with atherosclerotic cerebral infarction in a southern Han population

Yanmin Song, Qunfang Li, Lili Long, Ning Zhang, Yunhai Liu Department of Neurology, Xiangya Hospital, Central South University, Changsha, Hunan Province, People’s Republic of China Background: CD31, also called platelet endothelial cell invacare 9000 xt recliner wheelchair adhesion molecule-1 (PECAM-1), is thought to play a role in the pathol

read more

Effect of hypotensive hypovolemia and thoracic epidural anesthesia on plasma pro-atrial natriuretic peptide to indicate deviations in central blood volume in pigs: a blinded, randomized controlled trial

Rune B Strandby,1 Rikard Ambrus,1 Michael P Achiam,1 Amalie Henriksen,1 Jens P Goetze,2 Niels H Secher,3 Lars B Svendsen11Department of Surgical Gastroenterology; 2Department of banana ointment Clinical Biochemistry; 3Department of Anesthesiology, Rigshospitalet, University of Copenhagen, Copenhagen, DenmarkPurpose: Changes in plasma pro-atrial nat

read more